Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance
Clover Health (NASDAQ: CLOV) reported strong Q2 2024 financial results, showing significant improvements year-over-year. Total revenue grew 11% to $356.3 million, while GAAP Net Income from Continuing Operations reached $7.2 million, compared to a $28.9 million loss in Q2 2023. Adjusted EBITDA increased to $36.2 million from $9.9 million in the previous year.
The company's Insurance revenue grew 11.3% to $349.9 million, driven by strong member retention and intra-year growth. The Insurance MCR improved to 71.3% from 77.2% in Q2 2023. Based on these strong results, Clover Health has increased its full-year 2024 guidance, projecting Insurance Revenue of $1.35-$1.375 billion and Adjusted EBITDA of $50-$65 million.
Clover Health (NASDAQ: CLOV) ha riportato solidi risultati finanziari per il secondo trimestre del 2024, mostrando miglioramenti significativi rispetto all'anno precedente. Le entrate totali sono aumentate dell'11% raggiungendo $356,3 milioni, mentre l'utile netto GAAP dalle operazioni continuative ha raggiunto $7,2 milioni, rispetto a una perdita di $28,9 milioni nel secondo trimestre del 2023. L'EBITDA rettificato è aumentato a $36,2 milioni da $9,9 milioni dell'anno precedente.
Le entrate assicurative dell'azienda sono cresciute dell'11,3% arrivando a $349,9 milioni, sostenute da un forte tasso di fidelizzazione dei membri e da una crescita intra-anno. Il MCR delle assicurazioni è migliorato al 71,3% rispetto al 77,2% del secondo trimestre del 2023. Sulla base di questi solidi risultati, Clover Health ha aumentato le sue previsioni per l'intero anno 2024, prevedendo un fatturato assicurativo di $1,35-$1,375 miliardi e un EBITDA rettificato di $50-$65 milioni.
Clover Health (NASDAQ: CLOV) reportó sólidos resultados financieros para el segundo trimestre de 2024, mostrando mejoras significativas año con año. Los ingresos totales crecieron un 11% alcanzando los $356.3 millones, mientras que el ingreso neto GAAP de operaciones continuas alcanzó los $7.2 millones, en comparación con una pérdida de $28.9 millones en el segundo trimestre de 2023. El EBITDA ajustado aumentó a $36.2 millones desde los $9.9 millones del año anterior.
Los ingresos de seguros de la empresa crecieron un 11.3% alcanzando los $349.9 millones, impulsados por una fuerte retención de miembros y crecimiento intra-anual. El MCR de seguros mejoró al 71.3% desde el 77.2% en el segundo trimestre de 2023. Basado en estos sólidos resultados, Clover Health ha aumentado su guía para el año completo 2024, proyectando ingresos por seguros de $1.35-$1.375 mil millones y un EBITDA ajustado de $50-$65 millones.
Clover Health (NASDAQ: CLOV)는 2024년 2분기 강력한 재무 결과를 보고하며, 전년 대비 상당한 개선을 보였습니다. 총 수익은 11% 증가하여 $356.3 백만에 달했고, 지속 운영으로 인한 GAAP 순이익은 $7.2 백만에 도달했습니다, 2023년 2분기에는 $28.9 백만의 손실이 있었습니다. 조정된 EBITDA는 $9.9 백만에서 $36.2 백만으로 증가했습니다.
회사의 보험 수익은 강한 회원 유지율과 연간 성장에 힘입어 11.3% 증가하여 $349.9 백만에 달했습니다. 보험 MCR은 77.2%에서 71.3%로 개선되었습니다. 이러한 강력한 결과를 바탕으로 Clover Health는 2024년 전체 연도 가이던스를 증가시켰습니다, 보험 수익을 $1.35-$1.375 billion 및 조정 EBITDA를 $50-$65 million으로 예상하고 있습니다.
Clover Health (NASDAQ: CLOV) a rapporté de solides résultats financiers pour le deuxième trimestre de 2024, montrant des améliorations significatives par rapport à l'année précédente. Les revenus totaux ont augmenté de 11% atteignant 356,3 millions de dollars, tandis que le bénéfice net GAAP des opérations continues a atteint 7,2 millions de dollars, comparé à une perte de 28,9 millions de dollars au deuxième trimestre 2023. Le EBITDA ajusté a augmenté à 36,2 millions de dollars contre 9,9 millions de dollars l'année précédente.
Les revenus d'assurance de l'entreprise ont augmenté de 11,3% atteignant 349,9 millions de dollars, soutenus par une forte rétention des membres et une croissance intra-annuelle. Le MCR de l'assurance s'est amélioré à 71,3% contre 77,2% au deuxième trimestre 2023. Sur la base de ces résultats solides, Clover Health a rehaussé ses prévisions pour l'année 2024, projetant des revenus d'assurance de 1,35 à 1,375 milliard de dollars et un EBITDA ajusté de 50 à 65 millions de dollars.
Clover Health (NASDAQ: CLOV) hat starke Finanzkennzahlen für das zweite Quartal 2024 vorgelegt und zeigt signifikante Verbesserungen im Vergleich zum Vorjahr. Der Gesamtumsatz stieg um 11% auf $356,3 Millionen, während der GAAP-Nettoertrag aus fortgeführten Betrieben $7,2 Millionen erreichte, verglichen mit einem Verlust von $28,9 Millionen im 2. Quartal 2023. Das bereinigte EBITDA erhöhte sich auf $36,2 Millionen von $9,9 Millionen im Vorjahr.
Der Versicherungsumsatz des Unternehmens wuchs um 11,3% auf $349,9 Millionen, unterstützt durch eine starke Mitgliederbindung und Wachstum im Laufe des Jahres. Der Versicherungs-MCR verbesserte sich auf 71,3% von 77,2% im 2. Quartal 2023. Basierend auf diesen starken Ergebnissen hat Clover Health seine Prognose für das gesamte Jahr 2024 angehoben und rechnet mit einem Versicherungsumsatz von $1,35-$1,375 Milliarden und einem bereinigten EBITDA von $50-$65 Millionen.
- Total revenue growth of 11% year-over-year to $356.3 million
- GAAP Net Income from Continuing Operations of $7.2 million, compared to a $28.9 million loss in Q2 2023
- Adjusted EBITDA increased to $36.2 million from $9.9 million year-over-year
- Insurance revenue grew 11.3% to $349.9 million
- Insurance MCR improved to 71.3% from 77.2% in Q2 2023
- Increased full-year 2024 guidance for Insurance Revenue and Adjusted EBITDA
- Star Rating recalculation from 3 to 3.5 Stars for the 2025 payment year
- Total restricted and unrestricted cash, cash equivalents, and investments decreased by 30% to $482.8 million
- Insurance members decreased from 82,526 to 80,261 year-over-year
Insights
Clover Health's Q2 2024 results demonstrate significant progress, with a notable shift to profitability. The company reported a
The
The updated guidance for 2024 is encouraging, with increased revenue expectations and a significant boost in projected Adjusted EBITDA to
Clover Health's technology-centric approach, particularly its Clover Assistant platform, appears to be yielding tangible results. The improved financial performance suggests that the company's strategy of empowering physicians through technology is gaining traction in the competitive Medicare Advantage market.
The company's ability to partner with a wider range of physicians due to its technology platform could be a significant differentiator. This flexibility may contribute to better member retention and potentially lower acquisition costs, which are important in the Medicare Advantage space.
The recent upgrade to a 3.5 Star Rating for the 2025 payment year is noteworthy. Higher star ratings typically lead to increased reimbursements from CMS and can enhance a plan's attractiveness to potential members, potentially driving future growth and profitability.
Clover Health's performance should be viewed in the context of the broader Medicare Advantage market. The sector is highly competitive, with large, established players dominating. Clover's ability to achieve profitability and grow revenue in this environment is commendable.
The company's focus on chronic disease management through its technology platform aligns well with market trends, as the aging population increases demand for such services. The improved MCR of 71.3% is particularly competitive, comparing favorably to many larger insurers.
However, investors should note that Clover's membership growth appears to have stalled, with 80,261 members as of June 30, 2024, compared to 82,526 a year earlier. While the company has improved its economics per member, sustainable long-term growth will likely require expanding its membership base.
Total Revenue growth for the Second Quarter of 2024 of
GAAP Net Income from Continuing Operations during the Second Quarter of 2024 of
Adjusted EBITDA profitability for the Second Quarter of 2024 of
Increases Full-Year 2024 guidance to Insurance Revenue of
FRANKLIN, Tenn., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today reported financial results for the second quarter 2024. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.
“I am delighted that our performance continues to validate Clover’s differentiated, technology-centric approach to healthcare, driven by our Insurance offering and its ability to generate meaningful returns while leading with physician-choice for our members,” said Clover Health CEO Andrew Toy. “Through our Clover Assistant technology and integrated care management platform, we aim to empower physicians to improve clinical outcomes and lower the total cost of care for people with chronic diseases. This allows us to partner with a much wider range of physicians than other plans. Our performance validates this key point of differentiation, and I believe positions us to thrive in the future of the Medicare Advantage market.”
The Company continued to build upon its strong start to the year, reporting strong performance for several key operating metrics and has improved its full-year 2024 guidance for revenue and profitability.
For the second quarter 2024, compared to second quarter 2023, GAAP Net income improved to
“During the second quarter, Clover's business fundamentals once again delivered strong financial results,” said Peter Kuipers, CFO of Clover Health. “First, top-line revenues grew by
Key Company highlights are as follows:
| Dollars in Millions | 2Q24 | 2Q23(2) | Change Between (%) | |||||||
| Insurance revenue | $ | 349.9 | $ | 314.4 | ||||||
| Net medical claims incurred | 249.4 | 242.8 | ||||||||
| Total revenue | 356.3 | 320.1 | ||||||||
| Insurance MCR | 71.3 | % | 77.2 | % | (590 bps) | |||||
| Insurance BER(3) | 76.1 | % | 82.1 | % | (600 bps) | |||||
| Salaries and benefits plus General and administrative expenses ("SG&A")(4) | $ | 99.9 | $ | 104.1 | (4.0)% | |||||
| Adjusted Salaries and benefits plus General and administrative expenses ("Adjusted SG&A")(4)(5) | 71.7 | 65.9 | ||||||||
| Net income (loss) from continuing operations | 7.2 | (28.9 | ) | Favorable(1) | ||||||
| Adjusted EBITDA(5) | 36.2 | 9.9 | ||||||||
| Total restricted and unrestricted cash, cash equivalents, and investments | $ | 482.8 | $ | 689.8 | (30.0)% | |||||
Financial Outlook
For full-year 2024, Clover Health is updating its guidance as follows:
| Current 2024 Guidance | Previous 2024 Guidance | ||
| Insurance revenue | |||
| Insurance MCR | |||
| Insurance BER(6) | N/A | ||
| Adjusted SG&A(6) | |||
| Adjusted EBITDA(6) | |||
Lives under Clover Management
| June 30, 2024 | June 30, 2023 | ||
| Insurance members | 80,261 | 82,526 | |
Earnings Conference Call Details
Clover Health’s management will host a conference call to discuss its financial results on Monday, August 5, at 5:00 PM Eastern Time. To access the call via telephone please dial 800-245-3047 (for U.S. callers) or 203-518-9765 (for callers outside the U.S.) and enter the conference ID: CLOVQ224. A live audio webcast will also be available online at: https://event.on24.com/wcc/r/4643549/90F8BD4EFDC6BDE3601CC8948AF5A379. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link and at Clover Health’s Investor Relations website at investors.cloverhealth.com, and will remain available for approximately 12 months.
Upcoming Investor Events & Conferences
- 2024 KeyBanc Technology Leadership Forum at 3:00 p.m. Eastern Time, August 6, 2024
- Canaccord Genuity 44th Annual Growth Conference at 2:00 p.m. Eastern Time, August 14, 2024
Any live and archived webcasts and presentations associated with the conferences listed above may be accessed on Clover Health’s Investor Relations website at: investors.cloverhealth.com/news-and-events/investor-events-presentations.
______________________________________
1 Not presented as a % change because the current or prior period amount is zero or the amount for the line item changed from a gain to a loss (or vice versa) and thus yields a result that is not meaningful.
2 The results of operations for the Company's former Non-Insurance segment have been reclassified as discontinued operations for all periods presented due to the Company's decision to not participate in the ACO Reach program for the 2024 performance year. Refer to Note 17 - Discontinued Operations within the Company's most recent Form 10-Q for additional information.
3 Insurance Benefits Expense Ratio (“BER”) is a Non-GAAP financial measure. A reconciliation of BER to Insurance Net medical claims incurred, net, the most directly comparable GAAP measure, is provided in a table immediately following the consolidated financial statements below. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A. Beginning in the second quarter 2024, the Company is presenting Insurance BER. Management believes that by adding quality improvement expenses into the Insurance BER calculation, this offers a clearer and more accurate representation of our investment in healthcare quality and member engagement, and more fully captures the cost of maintaining and enhancing the quality of care for our members.
4 Salaries and benefits plus General and administrative expenses ("SG&A") is the sum of Salaries and benefits plus General and administrative expenses presented as the GAAP measure in the condensed consolidated financial statements.
5 Adjusted SG&A (Non-GAAP) and Adjusted EBITDA (Non-GAAP) are Non-GAAP financial measures. Reconciliations of Adjusted SG&A (Non-GAAP) to SG&A and Adjusted EBITDA (Non-GAAP) to Net loss from continuing operations, respectively, the most directly comparable GAAP measures, are provided in the tables immediately following the consolidated financial statements below. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A.
6 Reconciliations of projected Adjusted SG&A (Non-GAAP) to projected SG&A, and projected Adjusted EBITDA (Non-GAAP) to Net loss from continuing operations, the most directly comparable GAAP measures, are not provided because Stock-based compensation, which is excluded from Adjusted SG&A (Non-GAAP) and Adjusted EBITDA (Non-GAAP), cannot be reasonably calculated or predicted at this time without unreasonable efforts. A reconciliation of projected Insurance BER (Non-GAAP) to projected Net medical claims incurred, net, the most directly comparable GAAP measure, is not provided because quality improvements, which are included in Insurance BER (Non-GAAP), cannot be reasonably calculated or predicted at this time without unreasonable efforts. Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding future events and Clover Health's future results of operations, financial condition, market size and opportunity, business strategy and plans, and the factors affecting our performance and our objectives for future operations. Forward-looking statements are not guarantees of future performance and you are cautioned not to place undue reliance on such statements. In some cases, you can identify forward looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "can," "could," "should," "would," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "outlook," "forecast," "guidance," "objective," "plan," "seek," "grow," "if," "continue" or the negative of these words or other similar terms or expressions that concern Clover Health's expectations, strategy, priorities, plans or intentions. Forward-looking statements in this press release include, but are not limited to, the following: statements under "Financial Outlook" and statements regarding expectations relating to potential improvements in Insurance MCR, operating expenses, Adjusted SG&A, Insurance BER, and the number of Clover Health's Insurance members, as well as the statements contained in the quotations of our executive officers, future capital needs and other expectations as to future performance, operations and results (including our updated guidance for full-year 2024). Statements regarding our Adjusted EBITDA profitability are also forward-looking, and are based on our current targets which are preliminary and are derived from our 2024 financial outlook. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by forward-looking statements in this press release. Forward-looking statements involve a number of judgments, risks and uncertainties, including, without limitation, risks related to: our expectations regarding results of operations, financial condition, and cash flows; our expectations regarding the development and management of our Insurance business; our ability to successfully enter new service markets and manage our operations; anticipated trends and challenges in our business and in the markets in which we operate; our ability to effectively manage our beneficiary base and provider network; our ability to maintain and increase adoption and use of Clover Assistant, including the expansion of Clover Assistant for external payors and providers under the brand name Counterpart Assistant; the anticipated benefits associated with the use of Clover Assistant, including our ability to utilize the platform to manage our medical care ratios; our ability to maintain or improve our Star Ratings or otherwise continue to improve the financial performance of our business; our ability to develop new features and functionality that meet market needs and achieve market acceptance; our ability to retain and hire necessary employees and staff our operations appropriately; the timing and amount of certain investments in growth; the outcome of any known and unknown litigation and regulatory proceedings; any current, pending, or future legislation, regulations or policies that could have a negative effect on our revenue and businesses, including rules, regulations, and policies relating to healthcare and Medicare; fluctuations in the price of our Class A common stock and our ability to comply with Nasdaq's listing requirements; our ability to maintain, protect, and enhance our intellectual property; general economic conditions and uncertainty; persistent high inflation and interest rates; and geopolitical uncertainty and instability. Additional information concerning these and other risk factors is contained under Item 1A. “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 14, 2024, as such risks may be updated in our subsequent filings with the SEC. The forward-looking statements included in this press release are made as of the date hereof. Except as required by law, Clover Health undertakes no obligation to update any of these forward-looking statements after the date of this press release or to conform these statements to actual results or revised expectations.
About Non-GAAP Financial Measures
We use Non-GAAP measures including Insurance BER, Adjusted EBITDA, Adjusted SG&A, and Adjusted SG&A as a percentage of revenue. These Non-GAAP financial measures are provided to enhance the reader's understanding of Clover Health's past financial performance and our prospects for the future. Clover Health's management team uses these Non-GAAP financial measures in assessing Clover Health's performance, as well as in planning and forecasting future periods. These Non-GAAP financial measures are not computed according to GAAP, and the methods we use to compute them may differ from the methods used by other companies. Non-GAAP financial measures are supplemental to and should not be considered a substitute for financial information presented in accordance with generally accepted accounting principles in the United States ("GAAP") and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Readers are encouraged to review the reconciliations of these Non-GAAP financial measures to the comparable GAAP measures, which are attached to this release, together with other important financial information, including our filings with the SEC, on the Investor Relations page of our website at investors.cloverhealth.com.
For a description of these Non-GAAP financial measures, including the reasons management uses each measure, please see Appendix A: "Explanation of Non-GAAP Financial Measures."
The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we aim to extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Visit: www.cloverhealth.com
Investor Relations Contact:
Ryan Schmidt
investors@cloverhealth.com
Press Contact:
Andrew Still-Baxter
press@cloverhealth.com
| CLOVER HEALTH INVESTMENTS, CORP. | |||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
| (Dollars in thousands, except share amounts) | |||||
| June 30, 2024 (Unaudited) | December 31, 2023 | ||||
| Assets | |||||
| Current assets | |||||
| Cash and cash equivalents | $ | 254,771 | $ | 116,407 | |
| Short-term investments | 9,661 | 12,218 | |||
| Investment securities, available-for-sale (Amortized cost: 2024: | 111,325 | 100,702 | |||
| Investment securities, held-to-maturity (Fair value: 2024: | 3,295 | 6,902 | |||
| Accrued retrospective premiums | 53,892 | 22,076 | |||
| Other receivables | 21,231 | 16,666 | |||
| Healthcare receivables | 66,739 | 64,164 | |||
| Surety bonds and deposits | 542 | 542 | |||
| Prepaid expenses | 14,517 | 14,418 | |||
| Other assets, current | 3,539 | 1,404 | |||
| Assets related to discontinued operations | 10,064 | 72,471 | |||
| Total current assets | 549,576 | 427,970 | |||
| Investment securities, available-for-sale (Amortized cost: 2024: | 102,973 | 120,208 | |||
| Investment securities, held-to-maturity (Fair value: 2024: | 791 | 793 | |||
| Property and equipment, net | 5,276 | 5,082 | |||
| Operating lease right-of-use assets | 2,858 | 3,382 | |||
| Other intangible assets | 2,990 | 2,990 | |||
| Other assets, non-current | 9,746 | 10,246 | |||
| Total assets | $ | 674,210 | $ | 570,671 | |
| CLOVER HEALTH INVESTMENTS, CORP. | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (Dollars in thousands, except share amounts) | |||||||
| June 30, 2024 (Unaudited) | December 31, 2023 | ||||||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities | |||||||
| Unpaid claims | $ | 199,266 | $ | 135,737 | |||
| Due to related parties, net | 1,284 | 1,363 | |||||
| Accounts payable and accrued expenses | 40,441 | 37,184 | |||||
| Accrued salaries and benefits | 32,400 | 20,951 | |||||
| Deferred revenue | 13 | 3,099 | |||||
| Operating lease liabilities | 1,491 | 1,665 | |||||
| Other liabilities, current | 843 | 1,017 | |||||
| Liabilities related to discontinued operations | 48,773 | 60,099 | |||||
| Total current liabilities | 324,511 | 261,115 | |||||
| Long-term operating lease liabilities | 2,519 | 2,998 | |||||
| Other liabilities, non-current | 22,292 | 20,164 | |||||
| Total liabilities | 349,322 | 284,277 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity | |||||||
| Class A Common Stock, | 41 | 40 | |||||
| Class B Common Stock, | 9 | 9 | |||||
| Additional paid-in capital | 2,517,959 | 2,461,238 | |||||
| Accumulated other comprehensive loss | (2,259 | ) | (2,370 | ) | |||
| Accumulated deficit | (2,171,556 | ) | (2,159,794 | ) | |||
| Less: Treasury stock, at cost; 14,574,401 and 7,912,750 shares held at June 30, 2024 and December 31, 2023, respectively | (19,306 | ) | (12,729 | ) | |||
| Total stockholders' equity | 324,888 | 286,394 | |||||
| Total liabilities and stockholders' equity | $ | 674,210 | $ | 570,671 | |||
| CLOVER HEALTH INVESTMENTS, CORP. | ||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | ||||||||||||||
| (Unaudited) | ||||||||||||||
| (Dollars in thousands, except per share and share amounts) | ||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||
| Revenues: | ||||||||||||||
| Premiums earned, net (Net of ceded premiums of | $ | 349,900 | $ | 314,383 | $ | 691,622 | $ | 631,469 | ||||||
| Other income | 6,360 | 5,755 | 11,560 | 10,661 | ||||||||||
| Total revenues | 356,260 | 320,138 | 703,182 | 642,130 | ||||||||||
| Operating expenses: | ||||||||||||||
| Net medical claims incurred | 248,347 | 244,262 | 513,509 | 519,051 | ||||||||||
| Salaries and benefits | 55,499 | 62,437 | 114,722 | 131,418 | ||||||||||
| General and administrative expenses | 44,424 | 41,710 | 88,993 | 99,354 | ||||||||||
| Premium deficiency reserve benefit | — | (5,138 | ) | — | (6,948 | ) | ||||||||
| Depreciation and amortization | 330 | 999 | 648 | 1,278 | ||||||||||
| Restructuring costs | 473 | 4,750 | 826 | 6,557 | ||||||||||
| Total operating expenses | 349,073 | 349,020 | 718,698 | 750,710 | ||||||||||
| Income (loss) from continuing operations | 7,187 | (28,882 | ) | (15,516 | ) | (108,580 | ) | |||||||
| Change in fair value of warrants | 17 | — | 17 | — | ||||||||||
| Interest expense | — | 7 | — | 7 | ||||||||||
| Loss on investment | — | — | 467 | — | ||||||||||
| Net income (loss) from continuing operations | 7,170 | (28,889 | ) | (16,000 | ) | (108,587 | ) | |||||||
| Net income from discontinued operations | 238 | 75 | 4,238 | 7,167 | ||||||||||
| Net income (loss) | $ | 7,408 | $ | (28,814 | ) | $ | (11,762 | ) | $ | (101,420 | ) | |||
| Per share data: | ||||||||||||||
| Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding | 487,483,087 | 479,163,752 | 487,575,520 | 479,819,237 | ||||||||||
| Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding | 495,179,955 | 479,163,752 | 487,575,520 | 479,819,237 | ||||||||||
| Continuing operations: | ||||||||||||||
| Basic earnings (loss) per share | $ | 0.01 | $ | (0.06 | ) | $ | (0.03 | ) | $ | (0.23 | ) | |||
| Diluted earnings (loss) per share | 0.01 | (0.06 | ) | (0.03 | ) | (0.23 | ) | |||||||
| Discontinued operations: | ||||||||||||||
| Basic earnings per share | 0.00 | 0.00 | 0.01 | 0.01 | ||||||||||
| Diluted earnings per share | 0.00 | 0.00 | 0.01 | 0.01 | ||||||||||
| Net unrealized gain on available-for-sale investments | 301 | 316 | 111 | 2,659 | ||||||||||
| Comprehensive income (loss) | $ | 7,709 | $ | (28,498 | ) | $ | (11,651 | ) | $ | (98,761 | ) | |||
| Operating Segments | ||||||||||||
| Insurance | Corporate/ Other | Eliminations | Consolidated Total | |||||||||
| Three Months Ended June 30, 2024 | (in thousands) | |||||||||||
| Premiums earned, net (Net of ceded premiums of | $ | 349,900 | $ | — | $ | — | $ | 349,900 | ||||
| Other income | 4,044 | 42,269 | (39,953 | ) | 6,360 | |||||||
| Intersegment revenues | — | 51,200 | (51,200 | ) | — | |||||||
| Net medical claims incurred | 249,406 | 4,965 | (6,024 | ) | 248,347 | |||||||
| Gross profit (loss) | $ | 104,538 | $ | 88,504 | $ | (85,129 | ) | $ | 107,913 | |||
| CLOVER HEALTH INVESTMENTS, CORP. | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| (Unaudited) | |||||||
| (Dollars in thousands) | |||||||
| Six Months Ended June 30, | |||||||
| 2024 | 2023 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (11,762 | ) | $ | (101,420 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation and amortization expense | 648 | 1,278 | |||||
| Stock-based compensation | 56,698 | 74,725 | |||||
| Change in fair value of warrants and amortization of warrants | 17 | — | |||||
| Accretion, net of amortization | (1,618 | ) | (1,853 | ) | |||
| Accrued interest earned | (463 | ) | (289 | ) | |||
| Net realized gains on investment securities | (5 | ) | (19 | ) | |||
| Loss on investment | 467 | — | |||||
| Premium deficiency reserve | — | (6,948 | ) | ||||
| Changes in operating assets and liabilities: | |||||||
| Accrued retrospective premiums | (31,816 | ) | 18,324 | ||||
| Other receivables | (4,565 | ) | 6,960 | ||||
| Surety bonds and deposits | — | — | |||||
| Prepaid expenses | (99 | ) | 2,901 | ||||
| Other assets | (2,125 | ) | 2,861 | ||||
| Healthcare receivables | (2,575 | ) | 19,341 | ||||
| Operating lease right-of-use assets | 524 | 157 | |||||
| Unpaid claims | 63,450 | (20,814 | ) | ||||
| Accounts payable and accrued expenses | 3,257 | 7,474 | |||||
| Accrued salaries and benefits | 11,449 | (4,311 | ) | ||||
| Deferred revenue | (3,086 | ) | 113,537 | ||||
| Other liabilities | 1,954 | 281 | |||||
| Operating lease liabilities | (653 | ) | (508 | ) | |||
| Net cash provided by operating activities from continuing operations | 79,697 | 111,677 | |||||
| Net cash (used in) provided by operating activities from discontinued operations | (9,005 | ) | 20,528 | ||||
| Net cash provided by operating activities | 70,692 | 132,205 | |||||
| Cash flows from investing activities: | |||||||
| Purchases of short-term investments, available-for-sale, and held-to-maturity securities | (51,670 | ) | (74,156 | ) | |||
| Proceeds from sales of short-term investments and available-for-sale securities | — | 60,436 | |||||
| Proceeds from maturities of short-term investments, available-for-sale, and held-to-maturity securities | 66,651 | 90,997 | |||||
| Purchases of property and equipment | (842 | ) | (605 | ) | |||
| Net cash provided by investing activities | 14,139 | 76,672 | |||||
| Cash flows from financing activities: | |||||||
| Issuance of common stock, net of early exercise liability | 23 | 1,118 | |||||
| Repurchases of common stock | (1,772 | ) | — | ||||
| Treasury stock acquired | (4,805 | ) | (3,399 | ) | |||
| Net cash used in financing activities | (6,554 | ) | (2,281 | ) | |||
| Net increase in cash, cash equivalents, and restricted cash for discontinued and continuing operations | 78,277 | 206,596 | |||||
| Cash, cash equivalents, and restricted cash, beginning of period for discontinued and continuing operations | 176,494 | 186,213 | |||||
| Cash, cash equivalents, and restricted cash, end of period for discontinued and continuing operations | $ | 254,771 | $ | 392,809 | |||
| Reconciliation of cash and cash equivalents and restricted cash for discontinued and continuing operations | |||||||
| Cash and cash equivalents | $ | 254,771 | $ | 310,079 | |||
| Restricted cash | — | 82,730 | |||||
| Total cash, cash equivalents, and restricted cash for discontinued and continuing operations | $ | 254,771 | $ | 392,809 | |||
| Supplemental disclosure of non-cash activities | |||||||
| Performance year receivable | $ | — | $ | (377,239 | ) | ||
| Performance year obligation | — | 377,239 | |||||
| CLOVER HEALTH INVESTMENTS, CORP. | ||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | ||||||
| ADJUSTED EBITDA (NON-GAAP) RECONCILIATION | ||||||
| (in thousands)(1) | ||||||
| Three Months Ended June 30, | ||||||
| 2024 | 2023 | |||||
| Net income (loss) from continuing operations (GAAP): | $ | 7,170 | $ | (28,889 | ) | |
| Adjustments | ||||||
| Interest expense | — | 7 | ||||
| Depreciation and amortization | 330 | 999 | ||||
| Stock-based compensation | 27,900 | 36,108 | ||||
| Premium deficiency reserve benefit | — | (5,138 | ) | |||
| Restructuring costs | 473 | 4,750 | ||||
| Non-recurring legal expenses and settlements | 319 | 2,108 | ||||
| Adjusted EBITDA (Non-GAAP) | $ | 36,192 | $ | 9,945 | ||
(1) The table above includes Non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these Non-GAAP measures, see Appendix A.
| CLOVER HEALTH INVESTMENTS, CORP. | |||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | |||||||
| ADJUSTED SG&A (NON-GAAP) RECONCILIATION | |||||||
| (in thousands)(1) | |||||||
| Three Months Ended June 30, | |||||||
| 2024 | 2023 | ||||||
| Salaries and benefits | $ | 55,499 | $ | 62,437 | |||
| General and administrative expenses | 44,424 | 41,710 | |||||
| Total SG&A (GAAP) | 99,923 | 104,147 | |||||
| Adjustments | |||||||
| Stock-based compensation | (27,900 | ) | (36,108 | ) | |||
| Non-recurring legal expenses and settlements | (319 | ) | (2,108 | ) | |||
| Adjusted SG&A (Non-GAAP) | $ | 71,704 | $ | 65,931 | |||
| Total revenues (GAAP) | $ | 356,260 | $ | 320,138 | |||
| Adjusted SG&A (Non-GAAP) as a percentage of revenue | 20 | % | 21 | % | |||
(1) The table above includes Non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these Non-GAAP measures, see Appendix A.
| CLOVER HEALTH INVESTMENTS, CORP. | |||||||||||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | |||||||||||||||
| INSURANCE BENEFITS EXPENSE RATIO (NON-GAAP) RECONCILIATION | |||||||||||||||
| (in thousands)(1) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net medical claims incurred, net (GAAP): | $ | 249,406 | $ | 242,839 | $ | 515,482 | $ | 517,343 | |||||||
| Adjustments | |||||||||||||||
| Quality improvements | 16,733 | 15,132 | 34,938 | 35,520 | |||||||||||
| Insurance benefits expense, net (Non-GAAP) | $ | 266,139 | $ | 257,971 | $ | 550,420 | $ | 552,863 | |||||||
| Premiums earned, net (GAAP) | $ | 349,900 | $ | 314,383 | $ | 691,622 | $ | 631,469 | |||||||
| Insurance benefits expense ratio, net (Non-GAAP) | 76.1 | % | 82.1 | % | 79.6 | % | 87.6 | % | |||||||
(1) The table above includes Non-GAAP measures. Non-GAAP financial measures are supplemental and should not be considered a substitute for financial information presented in accordance with GAAP. For a detailed explanation of these Non-GAAP measures, see Appendix A.
CLOVER HEALTH INVESTMENTS, CORP.
Appendix A
Explanation of Non-GAAP Financial Measures
Non-GAAP Definitions
Adjusted EBITDA - A Non-GAAP financial measure defined by us as net loss from continuing operations before depreciation and amortization, loss (gain) on investment, stock-based compensation, premium deficiency reserve benefit, restructuring costs, and non-recurring legal expenses and settlements. Adjusted EBITDA is a key measure used by our management team and the board of directors to understand and evaluate our operating performance and trends, to prepare and approve our annual budget and to develop short and long-term operating plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA provide useful measures for period-to-period comparisons of our business. Accordingly, we believe that Adjusted EBITDA provides investors and others useful information to understand and evaluate our operating results in the same manner as our management and our board of directors.
Adjusted SG&A - A Non-GAAP financial measure defined by us as total SG&A less stock-based compensation and non-recurring legal expenses and settlements. We believe that Adjusted SG&A provides management, investors, and others a useful view of our operating spend as it excludes non-cash, stock-based compensation and expenses related to investments that management believes do not reflect the Company's core operating expenses. We believe that Adjusted SG&A as a percentage of revenue is useful to management, investors, and others because it allows us to measure our operational leverage as revenue scales.
Insurance Benefits Expense Ratio - A Non-GAAP financial measure defined by us as benefits expense ratio ("BER"). We calculate our Insurance BER by taking the total of Insurance net medical expenses incurred and quality improvements, and dividing that total by premiums earned on a net basis, in a given period. Quality improvements include expenses associated with activities that improve health outcomes, as defined by the U.S. Department of Health and Human Services ("HHS"), as well as those directly tied to enhancing healthcare quality, such as the Company's spend on health information technology, wellness and prevention programs, initiatives to reduce hospital readmissions, and our clinically focused Member Rewards program. We believe our Insurance BER is useful to management, investors, and others because it offers a clearer and more accurate representation of our investment in healthcare quality and member engagement, and gives a comprehensive view of costs related to maintaining and improving the quality of care of our members, which is crucial for sustaining member satisfaction and adherence to treatment regimens.
FAQ
What was Clover Health's (CLOV) revenue growth in Q2 2024?
How did Clover Health's (CLOV) net income change in Q2 2024 compared to Q2 2023?
What is Clover Health's (CLOV) updated full-year 2024 guidance for Insurance Revenue?
How did Clover Health's (CLOV) Adjusted EBITDA perform in Q2 2024?
What was Clover Health's (CLOV) Insurance MCR in Q2 2024?
